The health and economic benefits of influenza vaccination for healthy and at-risk persons aged 65 to 74 years

PharmacoEconomics

Volumn 16, Issue SUPPL. 1, 1999, Pages 63-71

  Nichol, Kristin L ^a,c   Goodman, Michael ^b  

^a UNIVERSITY OF MINNESOTA   (United States)

^b HEALTHPARTNERS RESEARCH FOUNDATION   (United States)

^c VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE;

AGED; CONFERENCE PAPER; CONTROLLED STUDY; FEMALE; GERIATRIC PATIENT; HEALTH CARE COST; HEALTH ECONOMICS; HIGH RISK PATIENT; HUMAN; IMMUNIZATION; INFLUENZA; INFLUENZA VACCINATION; MAJOR CLINICAL STUDY; MALE; OUTCOMES RESEARCH; PRIORITY JOURNAL; VIRUS INFECTION;

AGED; COHORT STUDIES; COMORBIDITY; DIRECT SERVICE COSTS; EUROPE; FEMALE; HOSPITALIZATION; HUMANS; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; MINNESOTA; PNEUMONIA, VIRAL; RISK FACTORS; VACCINATION;

EID: 0032713370     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-199916001-00009     Document Type: Conference Paper

References (38)

1. Couch RB. Advances in influenza virus vaccine research. Ann NY Acad Sci 1993; 685: 803-12
2. Barker WH. Excess pneumonia and influenza associated hospitalization during influenza epidemics in the United States, 1970-78. Am J Public Health 1986; 76: 761-5
3. Simonsen L, Clark MJ, Williamson GD, et al. The impact of influenza epidemics on mortality: introducing a severity index. Am J Public Health 1947; 87: 1944-50
4. Glezen WP, Serious morbidity and mortality associated with influenza epidemics. Epidemiol Rev 1982; 4: 25-44
5. Collins SD, Lehmann J. Excess deaths from chronic disease during influenza epidemics. US Public Health Service Publication 213, Washington, DC: US Government Printing Office, 1953: 1-21
6. Williams WW, Hickson MA, Kane MA, et al. Immunization policies and vaccine coverage among adults: the risk for missed opportunities. Ann Intern Med 1988; 108: 616-25
7. Centers for Disease Control and Prevention. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). 1998; 47 (RR-6)
8. Fedson DS, Hirota Y, Shin HK, et al. Influenza vaccination in 22 developed countries: an update to 1995. Vaccine 1997; 15: 1506-11
9. Nicholson KG, Snacken R, Palache AM. Influenza immunization policies in Europe and the United States. Vaccine 1995; 13: 365-9
10. Govaert Th ME, Thijs CTMCN, Masurel N, et al. The efficacy of influenza vaccination in elderly individuals. A randomized double-blind placebo-controlled trial. JAMA 1994; 272: 1661-5
11. Mullooly JP, Bennett MD, Hornbrook MC, et al. Influenza vaccination programs for elderly persons: cost-effectiveness in a health maintenance organization. Ann Intern Med 1994; 121: 947-52
12. Nichol KL, Margolis KL, Wuorenma J, et al. The efficacy and cost effectiveness of vaccination against influenza among elderly persons living in the community. N Engl J Med 1994; 331: 778-84
13. Nichol KL. The benefits of influenza vaccination for low, intermediate, and high risk seniors. Arch Intern Med 1998; 158: 1769-76
14. Foster DA, Talsma A, Furumoto-Dawson A, et al. Influenza vaccine effectiveness in preventing hospitalization for pneumonia in the elderly. Am J Epidemiol 1992; 136: 296-307
15. Ohmit SE, Monto AS. Influenza vaccine effectiveness in preventing hospitalization among the elderly during influenza type A and type B seasons. Int J Epidemiol 1995; 24: 1240-8
16. Fedson DS, Wajda A, Nicol JP, et al. Clinical effectiveness of influenza vaccination in Manitoba. JAMA 1993; 270: 1956-61
17. Ahmed AH, Nicholson KG, Nguyen-van T, et al. Effectiveness of influenza vaccination in reducing hospital admissions during the epidemic of 1989-90. Epidemiol Infect 1997; 118; 27-33
18. Puig-Barbera J, Marquez-Calderon S, Masoliver-Fores A, et al. Reduction in hospital admission for pneumonia in non-institutionalised elderly people as a result of influenza vaccination: a case-control study in Spain. J Epidemiol Community Health 1997; 51: 526-30
19. Bonvehi P, Nacinovich F, Ruttimann R, et al. Effectiveness of influenza vaccine in elderly people living in the community in Argentina [abstract no. H-137]. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1997 Sep 28-Oct 1: Toronto, Washington DC: American Society for Microbiology, 1997: 238
20. Ahmed AEH, Nicholson KG, Nguyen-Van-Tam JS. Reduction in mortality associated with influenza vaccine during 1989-90 epidemic. Lancet 1995; 346: 591-5
21. Fleming DM, Watson JM, Nicholas S, et al. Study of the effectiveness of influenza vaccination in the elderly in the epidemic of 1989-90 using a general practice database. Epidemiol Infect 1995; 115: 581-9
22. Gross PA, Hermogenes AW, Sacks HS, et al. The efficacy of influenza vaccine in elderly people. A meta-analysis and review of the literature. Ann Intern Med 1995; 123: 518-27
23. Riddiough MA, Sisk JE, Bell JC. Influenza vaccination. Cost-effectiveness and public policy. JAMA 1983; 249: 3189-95
24. Maucher JM, Gambert SR. Cost-effective analysis of influenza vaccination in the elderly. Age 1990; 13: 3-9
25. Centers for Disease Control and Prevention. Final results: Medicare influenza vaccine demonstration selected states, 1988-1992. MMWR 1993; 42: 601-4
26. Patriarca PA, Arden NH, Koplan JP, et al. Prevention and control of type A influenza infections in nursing homes. Benefits and costs of four approaches using vaccination and amantadine. Ann Intern Med 1987; 107: 732-40
27. Helliwell BE, Drummond MF. The costs and benefits of preventing influenza in Ontario's elderly. Can J Public Health 1988; 79: 175-9
28. Postma MJ, Jager JC, Reinders AR, et al. Standard for cost-effectiveness analysis: a Dutch study on influenza vaccination. Health System Sci 1997; 1: 413-24
29. Scott WG, Scott HM. Economic evaluation of vaccination against influenza in New Zealand. Pharmacoeconomics 1996; 9: 51-60
30. Nichol KL. Long-term success with the national health objective for influenza vaccination: an institution-wide model. J Gen Intern Med 1992; 7: 595-600
31. Margolis KL, Nichol KL, Wuorenma J, et al. Exporting a successful influenza vaccination program from a leaching hospital to a community outpatient setting. J Am Geriatr Soc 1992; 40: 1021-3
32. Health Care Financing Administration. Medicare Program. Proposed Changes to the Hospital Inpatient Prospective Payment Systems and Fiscal Year 1995 Rates. The Federal Register 1994; 59 (102); 27838-9
33. Laupacis A, Sackett DL, Roberts RS. An assessment of clinically useful measures of the consequences of treatment. N Engl J Med 1988; 318: 1728-33
34. Haddix AC, Shaffer PA. Cost-effectiveness analysis. In: Haddix AC, Teutsch SM, Shaffer PA, et al., editors. Prevention effectiveness: a guide to decision analysis and economic evaluation. New York: Oxford University Press, 1996: 103-29
35. Haddix AC, Teutsch SM, Shaffer FA, et al., editors. Prevention effectiveness; a guide to decision analysis and economic evaluation. Appendix 1. Productivity Loss Tables. New York: Oxford University Press, 1996: 187-92
36. Margolis KL, Nichol KL, Poland GA, et al. Frequency of adverse reactions to influenza vaccine in the elderly. A randomized, placebo-controlled trial. JAMA 1990; 264: 1139-41
37. Govaert TME, Thijs CTMCN, Masurel N, et al. Adverse reactions to influenza vaccine in elderly people: a randomized double-blind placebo-controlled trial. BMJ 1993; 307: 988-90
38. Honkanen PO, Keistinen T, Kivela SL. The impact of vaccination strategy and methods of information on influenza and pneumococcal vaccination covorage in the elderly population. Vaccine 1997; 15: 317-20